دورية أكاديمية
Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
| العنوان: | Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. |
|---|---|
| المؤلفون: | Lu WX; The Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Md 21201-1595, USA., Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC |
| المصدر: | Nephron. Clinical practice [Nephron Clin Pract] 2005; Vol. 101 (2), pp. c79-86. Date of Electronic Publication: 2005 Jun 20. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Karger Country of Publication: Switzerland NLM ID: 101159763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1660-2110 (Electronic) Linking ISSN: 16602110 NLM ISO Abbreviation: Nephron Clin Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel : Karger, c2003- |
| مواضيع طبية MeSH: | Erythropoietin/*therapeutic use , Kidney Failure, Chronic/*drug therapy , Kidney Failure, Chronic/*mortality, Aged ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Quality of Health Care ; Recombinant Proteins ; Retrospective Studies ; Survival Rate |
| مستخلص: | Background: Recombinant human erythropoietin (rHuEPO) is recommended pre-dialysis to correct the anemia of chronic kidney disease. This study evaluated the impact of pre-dialysis rHuEPO on mortality in incident end-stage renal disease (ESRD) patients with varying levels of pre-ESRD care. Methods: The study included 15,807 individuals whose exposure to rHuEPO was determined from HCFA 2728 forms. Results: Median follow-up after starting dialysis was 32.8 months. Pre-ESRD rHuEPO use occurred in only 3,994 (25.3%) subjects and was more common in individuals with insurance, currently employed, started on outpatient dialysis, and initiated on peritoneal dialysis. During the study, 8,608 (54.5%) patients died. The risk of death was lower for rHuEPO-treated patients versus non-treated (relative risk 0.87, 95% CI 0.82-0.92). The survival benefit with rHuEPO was greatest early after dialysis initiation (relative risk at 1 vs. 7 years post-dialysis 0.73, 95% CI 0.66-0.80 vs. 0.87, 95% CI 0.82-0.92, respectively), did not vary across several surrogates for quality of care, and was greatest in those with the highest achieved hematocrit pre-ESRD. Conclusion: Pre-dialysis rHuEPO confers a survival benefit that depends on achieved hematocrit and diminishes post-dialysis, but is independent of several surrogates for quality of care except for insurance status pre-ESRD. (Copyright 2005 S. Karger AG, Basel.) |
| المشرفين على المادة: | 0 (Recombinant Proteins) 11096-26-7 (Erythropoietin) |
| تواريخ الأحداث: | Date Created: 20050625 Date Completed: 20060713 Latest Revision: 20111117 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1159/000086226 |
| PMID: | 15976508 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1660-2110 |
|---|---|
| DOI: | 10.1159/000086226 |